Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study

You likely can't join if

• Participants will be excluded from the study if they meet any of the following criteria: 1. Major illness or recent major surgery unrelated to MCT8 deficiency (in the principal investigator’s judgement), defined as: • Conditions requiring repeated hospitalizations that are likely to confound ability to participate in the trial. • Major illness in the 3 months prior to the Screening Visit that is likely to confound the ability of the participant to participate fully within the trial and/or confound the assessment of serum total T3 and/or safety.• Major surgery within the 3 months prior to the Screening Visit or planned to take place during the study, including but not limited to major abdominal/thoracic/neurosurgical procedures. • Major/minor abdominal and/or maxillofacial surgery that may inhibit the administration and/or absorption of study drug. 2. Body weight <10 kg at the Screening Visit. 3. Patients who are participating, or intend to participate, in other therapeutic and/or interventional clinical studies during the study period. 4. History of allergic reactions to components of tiratricol or any excipients in the IP. 5. Participants with any contra-indication for treatment with tiratricol or any excipients in the IP. 6. Participants who have used other T3 analogues, levothyroxine, propylthiouracil, or other antithyroid medications within 6 weeks of screening